Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier

Leuk Lymphoma. 2009 Jun;50(6):865-7. doi: 10.1080/10428190903030866.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Fluorodeoxyglucose F18 / pharmacokinetics
  • Humans
  • Incidental Findings
  • Lung / drug effects
  • Lung / metabolism
  • Lung / pathology
  • Lung Diseases / chemically induced
  • Lung Diseases / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Positron-Emission Tomography / methods*
  • Rituximab
  • Tomography, X-Ray Computed / methods*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Fluorodeoxyglucose F18
  • Rituximab